Patients who received Pavblu (aflibercept-ayyh), a biosimilar to Eylea HD (aflibercept), experienced no unexpected side effects and showed stable vision outcomes, according to findings presented at the American Society of Retina Specialists (ASRS) annual meeting this past weekend in Long Beach, Calif.

Pavblu was FDA approved in August 2024 as a biosimilar to Eylea, a drug commonly used to treat several serious eye conditions such as neovascular (wet) age-related macular degeneration (AMD), macular edema after retinal vein occlusion (RVO), diabetic macular edema (DME) and diabetic retinopathy (DR). Aflibercept-ayyh was approved after clinical trials involving between 350 and 600 patients showed that it was clinically equivalent to the reference product in terms of safety and effectiveness

See Full Page